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Objectives. We report mortality, infarction, revascularization 
and repeat hospital admission events for 1 year after enrollment 
and randomization i the Thrombolysis in Myocardial Ischemia 
(TIMI) IIIB clinical trial. 
Background. The purpose of this trial was to investigate the 
role of a thrombolytic agent added to conventional medical 
therapies and to compare an early invasive management strategy 
to a more conservative early strategy in patients with unstable 
angina and non-Q wave myocardial infarction. 
Methods. There were 1,473 patients enrolled, and they received 
conventional nti-ischemic medical therapies. They were randomized 
to therapy with either tissue-type plasminogen activator (t-PA) or 
placebo and also to an early invasive management s rategy with 
coronary arteriography at 18 to 48 h, followed by revascularization as 
soon as possible if appropriate, or, alternatively, to an early conser- 
vative strategy with arteriography and revascularization reserved for 
failure of initial therapy to prevent recurrent ischemia. The primary. 
end point was a composite outcome variable and was assessed at 
42 days. Patients were then managed entirely at the discretion of 
their treating physician. Follow-up contacts were made at 1 year. 
Results. The incidence of death or nonfatal infarction for the 
t-PA- and placebo-treated groups was similar after I year (12.4% 
vs. 10.6%, p = 0.24). The incidence of death or nonfatal infarction 
was also similar after 1 year for the early invasive and early 
conservative strategies (10.8% vs. 12.2%, p = 0.42). A trial of this 
size should be able to detect differences in relative risk for death 
or infarction >1.81 with a power of 80% at a significance level 
(alpha) of 0.01. Revascularization by1 year was common, but was 
slightly more common with the early invasive than the early 
conservative strategy (64% vs. 58%, p < 0.001). This result was 
related entirely to a small difference in angioplasty rates (39% vs. 
32%, p < 0.001) inasmuch as rates of bypass grafting by 1 year 
were equivalent (30% in each group, p = 0.50). The high rate of 
revascularization in both strategies was accompanied by compa- 
rable clinical status at the 1-year follow-up contact. 
Conclusions. In this large study of unstable angina and non-Q 
wave myocardial infarction, the incidence of death and nonfatal 
infarction or reinfarction was low but not trivial after 1 year (4.3% 
mortality, 8.8% nonfatal infarction). An early invasive manage- 
ment strategy was associated with slightly more coronary angioplasty 
procedures but equivalent numbers of bypass surgery procedures 
than a more conservative early strategy of catheterization a d revas- 
cularization only for signs of recurrent ischemia. The incidence of 
death or nonfatal infarction, or both, did not differ after 1 year by 
strategy assignment, but fewer patients in the early invasive strategy 
group underwent later repeat hospital admission (26% vs. 33%, p 
< 0.001). Either strategy is appropriate for patient management; 
differences in hospital admissions and revascularization procedures, 
with their attendant costs, are likely to be minimal. 
(J Am CoU Cardiol 1995;26:1643-50) 
The Thrombolysis in Myocardial Ischemia (TIMI) IIIB trial 
was a multicenter clinical investigation designed to determine 
the safety and effectiveness of early intravenous thrombolytic 
treatment as well as either an early invasive or early conserva- 
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tive management approach in patients with unstable angina 
and non-Q wave myocardial infarction. The rationale for 
administration f a thrombolytic agent was the known involve- 
ment of fresh thrombus on the disrupted surface of coronary 
artery plaque in this syndrome. Several smaller clinical trials 
(1,2) had indicated that hrombolysis might be useful, but these 
trials lacked sufficient statistical power to provide a definitive 
answer. Other trials (3-5) had suggested that thrombolysis 
might be harmful. The rationale for comparison of early 
invasive and early conservative approaches topatient manage- 
ment was to test more rigorously two common patterns of 
clinical practice, that is, a strategy of early diagnostic atheter- 
ization with revascularization when appropriate or, alterna- 
tively, a more conservative strategy of medications and rest 
followed by a noninvasive assessment ofischemia. Outcomes at 
the primary end point of 6 weeks have been presented 
previously (6). Results at that point demonstrated no differ- 
ence in outcome between thrombolytic- and placebo-treated 
patients and no difference in outcome between early invasive 
and early conservative strategies. The purpose of the current 
report was to provide information on the occurrence of clinical 
events after 1 year. 
Methods 
Patient selection. Details of the TIMI IIIB protocol have 
been reported elsewhere (6). In brief, the study population 
consisted of 1,473 men and women enrolled through 25 
participating centers. Ages ranged from 21 to 79 years; how- 
ever, patients 75 to 79 years old were eligible for only a brief 
period during enrollment. Patients were required to have chest 
discomfort at rest suggestive of myocardial ischemia, lasting 
->5 min but -<6 h, that occurred within 24 h of the time of 
enrollment. They were required to have either transient ST 
segment elevation or transient or persistent ST segment de- 
pression or T wave inversion on the qualifying electrocardio- 
grams (ECGs). No ECG changes were required if a patient 
had a documented history of coronary artery disease. Patients 
were excluded if they had experienced a myocardial infarction 
within the preceding 21 days, had undergone coronary arte- 
riography within the preceding 30 days, had coronary angio- 
plasty performed within 6 months, had coronary bypass urgery 
at any time or were women of childbearing potential. Other 
exclusion criteria were presence of pulmonary edema, con- 
firmed blood pressure >180/100 mm Hg, any contraindication 
to thrombolytic therapy, left bundle branch block, a coexistent 
severe illness or use of oral anticoagulant agents. 
Management. All patients were admitted to the hospital 
and received bed rest, oxygen and antiischemia medications, 
which included a beta-adrenergic receptor antagonist (meto- 
prolol, 50 mg orally every 12 h), a calcium channel antagonist 
(diltiazem, 30 mg orally every 8 h) and a long-acting oral 
nitrate (isosorbide dinitrate, 10 mg orally every 8 h or larger 
doses if required). Intravenous nitroglycerin was permitted at 
the discretion of the treating physician. Intravenous heparin 
was to be administered to maintain the activated partial 
thromboplastin mes at 1.5 to 2.0 times the control values for 
72 to 96 h. A 5,000-U bolus was to be given to patients not 
already receiving heparin. Aspirin (325 mg daily orally) was to 
begin on the second ay and continue for I year. 
Randomization. A 2 x 2 factorial design was used to assign 
patients to treatment with tissue-type plasminogen activator 
(t-PA) or placebo and to an early invasive or early conservative 
management strategy. The dose of t-PA was 0.8 mg/kg over 
90 min and was given according to an accelerated regimen (6). 
In the early invasive strategy, catheterization with left ventricu- 
lography and coronary angiography were specified to be per- 
formed 18 to 48 h after randomization. Coronary angioplasty 
was required if a culprit lesion could be identified and the 
coronary anatomy was appropriate in the judgment of the 
operator. Coronary artery bypass grafting was to be performed 
as soon as feasible in those patients judged to be appropriate 
candidates for surgical revascularization. I  the early conser- 
vative strategy, catheterization and angiography were not 
performed during the first 6 weeks unless there was evidence of 
failure of initial medical therapies to prevent recurrent isch- 
emia. Failure was judged to have occurred if there were one or 
more episodes of ischemic hest pain that were associated with 
ECG changes of ST segment elevation or depression, >20 rain 
of ST segment deviation on 24-h Holter monitor ecording, a
"high risk" response on an exercise test or thallium scintigram, 
rest angina requiring readmission to the hospital during the 
first 6 weeks after enrollment or Canadian Cardiovascular 
Society class III or IV angina with a positive exercise test. 
Patients randomly assigned to early conservative strategy in 
whom initial therapy failed and who required catheterization 
were then managed in a manner similar to those in the early 
invasive strategy. After the 6-week visit, patient management 
was at the discretion of the treating physician. 
Follow-up. Patients were contacted by telephone -1 year 
after their initial randomization (range 365 to 550 days). At 
this contact, vital status and clinical events were ascertained. 
The events of interest were myocardial infarction, revascular- 
ization or repeat revascularization, hospital admission for 
unstable angina, number of days of repeat hospital admission 
since discharge, medication use and anginal status. 
Statistical methods. The Cox proportional model (7) was 
used to analyze 1-year event rates and performance ofproce- 
dures, including appropriate regression terms for a 2 × 2 
factorial design. If necessary, subgroup interaction terms were 
also included in the Cox model to determine whether one 
subgroup of patients responded ifferently to the TIMI IIIB 
treatments han the complementary subgroup. Event rates 
were estimated using the method of Kaplan and Meier (8), and 
direct comparisons between treatments or strategies were 
performed using the log-rank statistic. Comparison of mean 
values and proportions between the two treatments orthe two 
strategies was performed using the two-sample t-test and the 
chi-square test, respectively. To account for the large number 
of statistical comparisons made in the trial, including those 
made here, only p values <0.01 were considered to be statis- 
tically significant, and p values <0.001 were considered to 
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Table 1. Clinical Events Through 1-Year Follow-Up 
Early Early 
Invasive Conservative 
All Pts t-PA Placebo p Strategy Strategy p 
(n = 1,473) (n = 729) (n = 744) Value* (n = 740) (n = 733) Valuer 
Death 
HD 2.0 2.1 2.0 0.96 2.2 1.9 0.73 
6 wk 2.2 2.3 2.0 0.68 2.3 2.0 0.74 
1 yr 4.3 4.3 4.2 0.94 4.1 4.4 0.79 
MI 
HD 5.2 6.4 4.0 0.04 5.5 4.9 0.59 
6 wk 6.1 7.4 4.9 0.04 5.8 6.5 0.67 
1 yr 8.8 9.9 7.7 0.12 8.3 9.3 0.51 
Death or MI 
HD 6.5 7.7 5.4 0.07 6.9 6.1 0.56 
6 wk 7.5 8.8 6.2 0.05 7.2 7.8 0.69 
1 yr ll.5 12.4 10.6 0.24 10.8 12.2 0.42 
*Tissue-type plasminogen activator (t-PA) versus placebo, tEarly invasive versus early conservative strategy. For 
hospital discharge (HD), data presented are percent of patients (Pts), with p values obtained using the chi-square statistic. 
For 6 weeks and 1 year, data are event rates in percent estimated using the Kaplan-Meier method, with p values obtained 
using the log-rank statistic. MI = myocardial infarction. 
provide strong evidence against he null hypothesis. The study 
was originally designed to detect a20% reduction in the initial 
therapy end point at 6 weeks for the t-PA versus placebo 
comparison and a 30% reduction in early invasive versus early 
conservative strategy end point at 6 weeks (6). Separate power 
calculations were made to determine the relative risks after 1 
year for the end points of death, myocardial infarction and 
death or myocardial infarction that could be detected with 
80% power when testing at the prespecified 0.01 alpha level 
(9). The relative risks were 2.35, 1.81 and 1.81, respectively, for 
both the comparison of t-PA versus placebo and the compar- 
ison of the two strategies. Data for this current report were 
based on the Coordinating Center analysis files created on 
June 30, 1994. 
Results 
Patients. The 1,473 patients enrolled were each assigned to 
one of the four groups created by the 2 x 2 factorial 
randomization. The majority of patients enrolled were white; 
33% were women; and many had a history of hypertension, 
angina or previous myocardial infarction. Seventy-five percent 
of the patients had ECG changes at the time of enrollment: 
33% had ST segment depression, and almost 50% had T wave 
inversion; 33% had a non-Q wave myocardial infarction. The 
initial report of the TIMI IIIB trial presented ata on out- 
comes by the 6-week visit (6). 
Comparison of t-PA and placebo. At 1 year after enroll- 
ment there were no differences in the occurrence of death on 
myocardial infarction, or both combined, between the patients 
randomized to t-PA or placebo (Table 1). A difference in the 
rates of myocardial infarction that had been noted at 6 weeks 
(7.4% vs. 4.9%, p -- 0.04) had narrowed and was not significant 
at 1 year (9.9% vs. 7.7%, p = 0.12). Kaplan-Meier estimated 
rates of the combined end point of death or infarction over 1 
year were 12.4% for the t-PA randomized group and 10.6% for 
the placebo randomized group (p = 0.24) (Fig. 1, top). 
It was observed at 6 weeks that there were higher ates of 
Figure 1. One-year cumulative rates of death or myocardial infarction 
by randomized assignments in TIMI IIIB. Top, Comparison of tissue- 
type plasminogen activator (TPA) and placebo therapies. Bottom, 
Comparison of early invasive and early conservative strategies. 
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Table 2. Cumulative Event Rates at 1 Year for Patients with Non-Q Wave Myocardial Infarction and Unstable Angina 
p Early Invasive Early Conservative p 
t-PA Placebo Value* Strategy Strategy, Value? 
Pts with evolving non-Q wave MI n - 492 n 5{11 n = 484 n = 509 
Death 5.2 6.2 (7.62 5.2 6.3 0.59 
MI 8.8 8.5 0.93 7.7 9.8 0.44 
Death or M1 12.5 12.Z 0.99 11.1 14.0 0.35 
Stroke 1.7 1.3 0.67 1.2 1.9 0.57 
Pts with unstable angina n 234 n - 243 n = 254 n - 223 
Death 3.9 3.3 11.57 3.6 3.6 0.98 
MI 10.5 7.3 0.07 8.6 9.1 0.81 
Death or MI 12.5 9.7 0.13 10.7 11.5 0.74 
Stroke 1.8 1.0 0.26 1.9 1.0 0.24 
*Tissue-type plasminogen activator (t-PA) versus placebo. ?Early invasive versus early conservative strategy. Data presented are number of patients (n) or estimated 
event rates in percent by Kaplan-Meier method: p values from the log-rank statistic. Other abbreviations as in Table 1. 
death and infarction in the subgroup of patients with unstable 
angina assigned to t-PA therapy than among those assigned to 
placebo. By 1 year the difference had diminished, as shown in 
Table 2. 
Comparison of early invasive and early conservative strat- 
egies. At 1 year after enrollment, there was no difference in 
the incidence of death or myocardial infarction between the 
patients randomized to early invasive or early conservative 
strategies (Table 1). Kaplan-Meier estimated rates of the 
combined end point of death or infarction over 1 year were 
10.8% for the early invasive group and 12.2% for the early 
conservative group (p = 0.42) (Fig. 1, bottom). There also 
were no differences in event rates when patients were catego- 
rized as having non-Q wave myocardial infarction or unstable 
angina (Table 2). 
At the 6-week evaluation, more patients randomized to the 
early conservative strategy had a repeat hospital admission 
than those randomized to the early invasive strategy, and the 
total number of days of repeat hospital admission also was 
greater. After 1 year these differences were still apparent 
(Table 3). Overall, 29% of enrolled patients had a repeat 
hospital admission by 1 year, accounting for 5,686 hospital 
days. In the early invasive group, 26% of patients had a repeat 
hospital admission compared with 33% in the early conserva- 
tive strategy group (p < 0.005). There was a slightly greater 
total number of days of repeat hospital admission in the early 
conservative group, but the difference after 1 year was no 
longer significant. More patients with unstable angina had a 
repeat hospital admission by 1 year than patients with a non-Q 
wave myocardial infarction (31% vs. 26%, p = 0.038); they also 
reported less angina at the 1-year contact, and they used 
similar numbers of antianginal medications. 
Catheterization and revascularization. The performance 
of invasive procedures is shown in Table 4. Virtually all of the 
patients assigned to early invasive strategy underwent cathe- 
terization. In the early conservative strategy, 64% of the 
Table 3. Repeat Hospital Admission, Anginal Status and Antianginal Medication Use 
Early Invasive Early Conservative Pts With Pts With 
All Pts Strategy Strategy p NQMI Unstable Angina p 
(n 1,473) (n - 740) (n 733) Value* (n - 477) (n = 993) Value? 
Pts with repeat hospital admission 
By 6 wk 155 (l l) 55 (8) 100 (14) < 0.001 42 (9) 113 (12) 0.170 
By 1 yr 429 (29) 191 126) 238 (33) < 0.005 122 (26) 306 (31) 0.038 
Duration of repeat hospital admission (days) 
By 6 wk 1,295 365 930 < (I.001 393 902 < 0.001 
By 1 yr 5,680 L743 2.943 0.711 2,083 3,602 0.005 
Antianginal medications at 1 yr 
0 366 (27) 198 (31!) 1~8 (25) 242 (27) 123 (28) 
1 483 (36} 242 (36) 241 (36) 314 (35) 167 (39) 
2 312 (23) 148 (22) 164 (25) 219 (24) 93 (22) 
3 171 (13) 76 (11) 95 (14) 0.146 122 (14) 49 (11) 0.321 
CCS status at 1 yr 
No angina 945 (7il) 478 (71) 467 (69) 616 (68) 327 (75) 
Class I or 11 2t;l (22) 141 (21) 150 (22) 209 (23) 81 (19) 
Class III or IV I 11 (8) 53 (8) 58 (91 0.732 82 (9) 29 (7) 0.033 
*Early invasive versus early conservative strategy. ?Patients (Pts) with non-Q wave myocardial infarction (NQMI) versus patients with unstable angina. Data 
presented are number (%) of patients, unless otherwise indicated. CCS = Canadian Cardiovascular Society class. 
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Table 4. Catheterization and Revascularization by Randomized Assignments 
Early Invasive Early Conservative 
All Pts t-PA Placebo p Strategy Strategy p 
(n = 1,473) (n = 729) (n = 744) Value* (n = 740) (n = 733) Valuel 
Catheter~ation 
HD 78 75 80 0.04 98 57 <0.001 
6 wk 81 80 83 0.08 98 64 < 0.001 
1 yr 86 83 88 0.03 99 73 <0.001 
PTCA 
HD 30 29 31 0.52 37 23 < 0.001 
6 wk 32 31 33 0.53 38 26 < 0.001 
1 yr 36 35 36 0.62 39 32 < 0.001 
CABG 
HD 21 19 23 0.11 24 18 0.003 
6 wk 24 23 25 0.22 25 23 0.17 
1 yr 30 29 31 0.27 30 30 0.50 
PTCAor 
CABG 
HD 50 47 53 0.04 60 40 < 0.00t 
6 wk 55 53 57 0.07 61 48 < 0.001 
1 yr 61 59 63 0.09 64 58 < 0.001 
*Tissue-type piasminogen activator (t-PA) versus placebo. #Early invasive versus early conservative strategy. For 
hospital discharge (HD), data presented are percent of patients (Pts), with p values obtained using the chi-square 
statistic. For 6 weeks and 1 year, data are event rates in percent estimated using the Kaplan-Meier method, with p values 
obtained using the log-rank statistic. CABG = coronary artery bypass grafting, PTCA = percutaneous transluminal 
coronary angioplasty. 
patients had undergone catheterization by 6 weeks, and 73% 
had done so by the 1-year contact. Overall, coronary angio- 
plasty was performed in 36% of enrolled patients, coronary 
bypass surgery in 30% and one or the other form of revascu- 
larization in the majority (61%) of patients in this trial by 1 
year. 
Coronary angioplasty was performed by the 1-year contact in 
39% of patients assigned to the early invasive strategy and in 
32% of patients assigned to the early conservative strategy, a 
small but statistically significant difference (Table 5). Most of 
the angioplasty procedures had been performed by 6 weeks Catheterization 
after enrollment. From 6 weeks to 1 year, only 2% of patients By 6 wk 98 
By 1 yr 99 
assigned to early invasive strategy who had not previously PTCA 
undergone angioplasty after enrollment underwent ew coro- By 6 wk 38 
nary angioplasty compared with four times as many, or 8%, of New, 6 wk-1 yr* 2 
corresponding early conservative strategy group patients (p < Repeat, 6 wk-1 yrt 16 
0.001). An equivalent number of early invasive and early PTCA at lyr 39 
conservative strategy group patients who had undergone an- CABG 
gioplasty by 6 weeks had repeat angioplasty procedures per- By 6 wk 25 
New, 6 wk-1 yr* 7 
formed by 1 year (16% and 17%, respectively, p = 0.555). Repeat, 6wk-1 yrt 0 
Coronary bypass urgery was performed by 1 year in 30% of CABG at 1 yr 30 
patients in both early invasive and early conservative strategies, eTCh or CABG 
Between 6 weeks and 1 year, new revascularization byeither By 6 wk 61 
angioplasty or bypass urgery in patients without revascular- New, 6 wk-1 yr* 6 
ization before the 6-week visit was performed in 6% of early Repeat, 6wk-1 yrl 10 
Revascularization at 1 yr 64 invasive strategy group patients and in 19% of early conserva- 
tive strategy group patients (p < 0.001). By 1 year the 
difference in revascularization with either angioplasty or by- 
pass grafting, although modest (64% vs. 58%, p < 0.001), was 
entirely a result of the small difference in angioplasty proce- 
dures. 
Nonrandomized subgroups. The TIMI IIIB protocol con- 
tained an analysis of the incidence of the combined end point 
of death or myocardial infarction in 14 prospectively defined 
Table 5. Initial and Repeat Procedures by Treatment Strategy 
Early Early 
Invasive Conservative 
Strategy Strategy p Value 
(n = 740) (n = 733) (log-rank statistic) 
64 < 0.001 
73 < 0.001 
26 < 0.001 
8 < 0.001 
17 0.555 
32 < 0.001 
23 0.169 
9 0.205 
0 
30 0.503 
48 < 0.001 
19 < 0.001 
10 0.998 
58 < 0.001 
*New procedures are based on number of patients who had not previously 
had the procedure from enrollment to 6-week visit, tRepeat procedures are 
based on number of patients who had the procedure by 6 weeks. Data presented 
are estimated event rates in percent by Kaplan-Meier method. Percentages do
not add directly because of patients (n = 64) who had both coronary angioplasty 
(PTCA) and bypass urgery. (CABG) by 1 year. 
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Table 6. Death or Myocardial Infarction, 1-Year Life-Table Rates: Cox Proportional Hazards Analysis 
Early Early 
Invasive Conservative 
t-PA Placebo Strategy Strategy 
(n = 729) (n = 744) (n = 740) (n = 733) 
Baseline No. of Event No. of Event p Interaction No. of Event No. of Event p Interaction 
Characteristic Pts Rate Pts Rate Value* p Valuer Pts Rate Pts Rate Value* p Valuer 
Unstable angina 492 I2.5 501 9.7 0.13 484 10.7 509 11.5 0.74 
Non-O wave MI 234 12.5 243 12.4 0.99 0.36 254 11.1 223 14.0 0.35 0.59 
ASA <24 h 336 15.6 369 11.2 0.07 352 12.9 353 13.7 0.84 
No ASA <24 h 393 9.7 375 9.9 0.93 0.20 388 8.8 380 10.9 0.35 0.59 
Age ->65 yr 224 17.0 248 14.9 0.48 241 12.5 231 19.5 0.03 
Age <65 yr 505 10.4 496 8.4 0.27 0.85 499 9.9 502 8.9 0.49 0.04 
Male 477 11.4 499 10.5 0.62 491 11.3 485 10.6 0.68 
Female 252 14.4 245 10.7 0.21 0.49 249 9.7 248 15.4 0.06 0.08 
Prior MI 268 12.(I 300 11.1 0.71 295 11.7 273 11.4 0.92 
No prior MI 46l 12.6 444 10.2 0.23 0.64 445 10.2 460 12.6 0.27 0.44 
ST elevation 69 14.5 82 9.8 0.36 73 15.1 78 9.0 0.24 
No ST elevation 660 12.2 661 10.7 0.36 0.55 667 10.3 654 12.6 0.21 0.12 
ST depression 217 17.1 263 13.7 0.31 258 14.4 222 16.3 0.60 
No ST depression 511 10.4 480 8.9 0.36 0.84 481 8.9 510 10.5 0.42 0.95 
T wave changes 347 12.7 336 9.6 0.17 333 8.2 350 14.1 0.02 
No T wave changes 381 12.2 407 11.4 0.71 0.47 406 12.9 382 10.5 0.28 0.0l 
ST deviation 271 16.7 320 12.5 0.15 310 13.9 281 15.0 0.74 
No ST deviation 457 9.9 423 9.1 0.63 0.49 429 8.5 451 10.5 0.34 0.70 
Some ECG changes 525 13.4 559 11.0 0.21 542 10.8 542 13.5 0.18 
No ECG changes 204 9.9 184 9.4 0.82 0.70 198 10.8 190 8.5 0.43 0.19 
Pain to treatment <12 h 515 11.9 558 11.6 0.81 535 11.1 538 12.3 0.59 
Pain to treatment >12 h 204 13.8 173 6.5 0.(12 0.05 191 9.6 186 ll.4 0.56 0.82 
Heparin therapy 33 15.2 37 0.0 0.01 32 3.1 38 10.5 0.23 
No heparin therapy 696 12.3 707 11.1 0.47 0.99 708 11.1 695 12.3 0.54 0.33 
3 antianginal agents 103 18.6 91 18.9 0.99 97 16.8 97 20.7 0.48 
<3 antianginal agents 626 11.4 653 9.4 0.22 0.53 643 9.9 636 10.9 0.59 0.69 
New onset <7 days 101 14.9 122 6.6 0.04 115 9.7 108 11.2 0.71 
No new onset <7 days 494 12.0 497 11.2 0.65 0.09 497 10.9 494 12.2 0.58 0.95 
*Log-rank statistic. ]Cox model test of equal treatment effects in the two strata. ASA = aspirin; ECG = electrocardiographic; other abbreviations as in Table 1. 
subgroups of clinical interest. The prespecified level for statis- 
tical significance in these subgroup comparisons was p < 0.01. 
Results at 6 weeks have been presented previously. One-year 
life-table rates are shown in Table 6. There was consistency in
the overall findings in the subgroups evaluated. 
Discussion 
Unstable angina and non-Q wave myocardial infarction are 
increasingly common syndromes in clinical practice. Recent 
estimates indicate that they account for -750,000 hospital 
admissions every year in the United States and are increasing, 
whereas hospital admissions for acute Q-wave myocardial 
infarction are declining (10-12). Several natural history studies 
(13,14), most of them done during the era when the diagnosis 
of unstable angina was first recognized, documented that 
mortality rates during the first year after diagnosis were -10% 
and nonfatal infarction rates were -15%.  Development of 
effective medical therapies for unstable angina, including use 
of aspirin, heparin, beta-adrenergic receptor antagonists and 
calcium channel antagonists, has reduced these event rates in 
the first year to -4% and 8%, respectively (15-17). 
Throm~lysis. Improved understanding of the pathogene- 
sis of unstable angina and non-Q wave myocardial infarction 
has been acquired over the past decade. These syndromes are 
now considered to result from development of a completely or 
partially occlusive thrombus at the site of a fissured coronary 
plaque (18-20). It was therefore thought hat the addition of a 
thrombolytic agent to conventional therapies in these syn- 
dromes might reduce the early event rates still further (21-24). 
However, as shown in the initial TIMI IIIB report, no clinical 
benefit was found for the patients randomly assigned to receive 
intravenous t-PA along with other medications usually em- 
ployed for management of these syndromes (6). In fact, there 
was an early hazard of intracranial hemorrhage associated with 
administration of t-PA. 
Catheterization and revascularization. Catheterization 
and revascularization procedures are frequently used in pa- 
tients with unstable angina. One of the purported advantages 
of early performance of catheterization is the ability to triage 
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patients ooner to appropriate therapy with operation, angio- 
plasty or medical management, as well as to detect those 
patients without significant coronary disease who may need 
reassurance only. Periprocedural mortality rates in patients 
with unstable syndromes (1% to 3% for angioplasty, 2% to 8% 
for bypass urgery) as well as nonfatal infarctions (6% to 10% 
for angioplasty, 4% to 17% for bypass surgery) are slightly 
higher than they are in patients with stable angina undergoing 
revascularization procedures but are still acceptable inview of 
the overall higher risk for adverse events in these patients 
(11,25,26). Revascularization is usually followed by very low 
rates of recurrent ischemic events during the first year. 
Overall, the rate of catheterization by the 1-year visit was 
86% of patients enrolled in TIMI IIIB, with 36% undergoing 
coronary angioplasty, 30% undergoing coronary bypass urgery 
and 61% undergoing at least one of these revascularization 
procedures. The initial TIMI IIIB report noted that more 
catheterizations and revascularizations had been performed by 
the 6-week visit in the patients assigned to early invasive 
management s rategy than among those assigned to early 
conservative strategy. Smaller differences between these 
groups persisted after 1 year. Bypass urgery was used equally 
by 1 year in both early invasive and early conservative groups. 
With patients randomized to these early strategies, each group 
would be composed of approximately equal numbers of pa- 
tients with complex, multivessel disease. Left ventricular func- 
tion also would be equivalent. As clinical events in these 
patients evolved over the course of 1 year, it might therefore be 
anticipated that approximately equal proportions of both 
groups might require bypass urgery. This hypothesis suggests 
that both strategies are equally useful approaches for identi- 
fying patients with coronary artery disease who will require 
bypass urgery within 1 year. 
Coronary angioplasty was used at different rates in the two 
groups, and this difference remained at 1 year, although 
ultimately the difference was less at 1 year than it had been at 
6 weeks. One important contributing factor was the higher ate 
of new coronary angioplasty procedures performed after 6 
weeks in the early conservative group. These procedures, 
performed at four times the rate of the early invasive group, 
helped narrow the difference. The overall high rate of revas- 
cularization (61% of patients) also helps to explain the general 
equality of outcomes after 1 year. 
One unexplained favorable finding is the low rate of repeat 
angioplasty procedures in patients who had undergone coro- 
nary angioplasty before the 6-week visit. Of early invasivc 
strategy group patients with coronary angioplasty before 6 
weeks, 16% underwent a repeat procedure by 1 year. This 
proportion was the same for early conservative strategy pa- 
tients with coronary angioplasty before 6 weeks, among whom 
17% underwent a repeat procedure by 1 year. Inasmuch as 
angiographic restenosis rates after coronary angioplasty have 
been reported to be 25% to 50% (27-29), the observed rates of 
repeat angioplasty appear lower than might be expected. Rates 
of bypass urgery observed for the period from 6 weeks to 1 
year may account for some patients with restenosis, but these 
rates also were relatively low. However, it is also likely that not 
all patients with restenosis underwent repeat revascularization. 
Because follow-up catheterization was not required, the true 
angiographic restenosis rates cannot be determined. Approxi- 
mately 30% of patients in both strategies had symptoms at the 
1-year contact, and some of them may have had restenosis that 
was not documented with angiography or treated with repeat 
revascularization. Nevertheless, these data suggest that "clini- 
cal restenosis" is relatively low with contemporary coronary 
angioplasty performed at these centers. 
Revascularization generally has been considered a second- 
ary end point in unstable angina therapies, with death, nonfatal 
infarction, refractory angina or ongoing ischemia nd repeat 
hospital admission after discharge the most common primary 
end points. In the Veterans Administration Cooperative Study 
(30) of medical compared to surgical treatment, 34% of 
patients assigned initially to medical therapy had undergone a 
surgical revascularization within 2 years. This result is similar 
to that of the Canadian Multicenter Trial of aspirin and 
sulfinpyrazone (31), in which 32% of enrolled patients with 
unstable angina ultimately underwent bypass urgery within 2 
years. In the study of aspirin and warfarin therapy reported by 
the Antithrombotic Therapy in Acute Coronary Syndromes 
(ATACS) study group (32), 13% of enrolled patients under- 
went revascularization by 3 months. The rates and types of 
revascularization bserved in TIMI IIIB represent rates reflec- 
tive of current clinical practice that are based on available 
alternatives. In the early conservative strategy of TIMI IIIB, 
catheterization a d revascularization after enrollment until the 
time of the 6-week visit required objective vidence of isch- 
emia. After this visit, decisions were made solely by treating 
physicians. The net effect of this protocol most likely makes the 
results less subjective and more reliable than previous urveys 
of clinical practice. The results of TIMI IIIB also suggest hat 
revascularization has become incorporated into the manage- 
ment of unstable angina and non-Q wave infarction, even in 
those situations where conservative strategies are used initially. 
Future clinical studies of these acute syndromes will have to 
recognize this fact and probably will have to include ischemic 
complications of procedures as an end point. 
Study limitations. The TIMI IIIB study was designed to 
detect a 20% reduction in the initial therapy end point at 6 
weeks for the t-PA versus placebo comparison and a 30% 
reduction in early invasive versus early conservative strategy 
end point at 6 weeks (6). The trial had adequate statistical 
power for those comparisons. The 1-year comparisons of the 
end points of death or myocardial infarction, or both, were not 
considered in the original sample-size calculations. At the 
strict, prespecified significance level of 0.01, the negative 
findings at 1 year in the present study can reasonably exclude 
the presence of twofold differences in those end points for 
t-PA versus placebo and early invasive versus early conserva- 
tive strategies. 
Conclusions. In the present study of unstable angina and 
non-Q wave myocardial infarction, rates of mortality and 
nonfatal infarction or reinfarction were low but were not trivial 
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over 1 year after enrollment (4.3% mortality, 8.8% nonfatal 
infarctions). The 1-year esults confirm the earlier eport of a 
lack of benefit of the thrombolytic agent -PA. Overall the rate 
of revascularization was high (36% had coronary angioplasty, 
30% had bypass urgery), with only a slightly lower proportion 
of patients ultimately undergoing revascularization when as- 
signed to the early conservative strategy. As opposed to acute 
Q-wave myocardial infarction treated with thrombolytic ther- 
apy (33,34), where an early conservative approach led to a 50% 
reduction in the number of revascularization procedures per- 
formed by 1 year compared with an early invasive approach 
(72% vs. 36%), in the syndromes ofunstable angina nd non-Q 
wave myocardial infarction the early conservative approach 
appears to obviate the need for only a small percent of 
revascularization procedures, uggesting that only small cost 
savings could be achieved. Conversely, the early invasive 
strategy used here was associated with shorter initial hospital 
stays and fewer subsequent readmissions, which could poten- 
tially lead to greater cost savings and more expeditious patient 
management, perhaps offsetting some of the costs of additional 
procedures. However, with equivalent early and late outcomes 
in the two strategies ither one is acceptable, and in this regard 
physicians have the latitude to individualize the care of their 
patients with unstable angina and non-Q wave myocardial 
infarction. 
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